Medical diagnostic company Shimadzu Medical Systems USA reported on Monday the receipt of the US FDA 510(k) clearance for the patient side conventional radiographic/fluoroscopic (RF) table system, FLUOROspeed X1.
With immediate market launch, the company's new radiographic/fluoroscopic (RF) FLUOROspeed X1 table system offers a high image quality and a multitude of features that improve work flow and operator efficiencies which contributes to lower cost of care.
A part of the FLUOROspeed series, the company's new FLUOROspeed X1 with its 665lb static patient weight and 500lb all motion weight, easily performs both bariatric and routine daily fluoroscopic and radiographic exams. It is practically priced and comes equipped with a 17"x17" dynamic digital X-ray detector (FPD) in the table bucky allowing be used for both fluoroscopy as well as radiographic exams.
The 31.5-inch aperture opening between table top and deck also provides access for imaging patients in wheelchairs as well as fits in smaller rooms. Adding the second X-ray tube on an overhead rail, the FLUOROspeed X1's functionality and versatility increases exponentially, concluded the company.
Merck to acquire Terns Pharmaceuticals for USD6.7bn
Philips launches integrated IntraSight Plus platform to enhance coronary intervention efficiency
Hope Medicine reports first patient dosed in Phase III trial of HMI-115
Orsini chosen as single-source specialty pharmacy partner for Glaukos' Epioxa
Futura Medical reports positive home user test results for Eroxon and Intense variant
GSK secures Japan Orphan Drug status for lung cancer ADC
Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment
Glaukos launches Epioxa to advance incision-free treatment for keratoconus
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment
CMIC agrees agentic AI partnership with Bluenote
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD